- RecruitingPHASE3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
This study looks at combining two medicines, mirikizumab and tirzepatide, for adults with ulcerative colitis (UC) who are also overweight or obese. The goal is to see if this combination helps UC symptoms improve and also leads to significant weight loss.
For: Ulcerative Colitis · Obesity or OverweightUnited States · Austria · Belgium - RecruitingPHASE3
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
This study looks at a medicine called Mirikizumab for children and teenagers aged 2 to 19 with Ulcerative Colitis or Crohn's Disease. It checks how well the medicine works over a long time to help manage these conditions.
For: Ulcerative Colitis · Ulcerative Colitis Chronic · Inflammatory Bowel DiseasesUnited States · Austria · Belgium - Active not recruitingPHASE3
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called mirikizumab for adults with ulcerative colitis. It aims to see how well it helps reduce urgent bowel movements in people with moderate to severe disease, especially if other treatments haven't worked.
For: Ulcerative Colitis · Ulcerative Colitis ChronicUnited States · Belgium · Czechia - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
For: Crohn's DiseaseUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
For: Ulcerative ColitisUnited States · Argentina · Australia - RecruitingPHASE3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
This study looks at new medicines, mirikizumab and tirzepatide, for adults with Crohn's disease who are also overweight or have obesity. It wants to see if these treatments are safe and if they help manage Crohn's symptoms and potentially aid weight management.
For: Crohn's Disease · Obesity or OverweightUnited States · Austria · Belgium - RecruitingPHASE3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
This study is looking at a new medicine called mirikizumab for children and teenagers with Crohn's disease. It wants to find out if it's safe, works well, and how the body handles it. It will involve those who haven't responded well to other treatments.
For: Crohn's DiseaseUnited States · Austria · Belgium - RecruitingPHASE2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
This study is looking into new medicines, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis. Researchers want to see if these medicines are safe and if they can help people feel better.
For: Ulcerative Colitis · Ulcerative Colitis ChronicUnited States · Argentina · Belgium